

U.S. Serial No.: 09/294,298
Applicants: Richard L. Huganir, et al.
Filing Date: April 19, 1999
Group Art Unit: 1644
Examiner: Nolan, P.
Docket No.: 48235 (71699)

REMARKS

In the outstanding Office Action, the PTO took the position that non-coding sequences in Figures 1-3 need sequence number identifiers in the Brief Description of the Drawings. Applicants respectfully disagree on grounds already of record. However in the interest of furthering prosecution, Applicants submit herewith a revised Sequence Listing as required and related papers.

Attached to this submission is a Paper Copy of Sequence Listing (50 pages).

Applicants submit that the instant amendment to the specification to add requested sequence identifiers and the addition of the attached new sequence listing add no new matter.

It is noted that newly added SEQ ID Nos. 22, 23, and 24 are presented in Sequence Listing in the 5' to 3' directed as provided by the rules. 37 CFR 1.822 (c) (5). However, as shown in Figures 1-3, the sequences are presented in the 3' to 5' as is the convention and practice in the field of the invention.

Statement Accompanying Submission Of Sequence Listing

Provided herewith is a Paper Copy of a Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence has been assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823. An amendment directing entry of the Paper Copy of the Sequence Listing into the specification is provided above.

Applicants further provide a Computer Readable Form (CRF) corresponding to the Paper Copy of the Sequence Listing provided herewith. Pursuant to 37 C.F.R. § 1.821(g), Applicants' agent hereby states that the CRF corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' attorney further hereby states that the contents of the Paper Copy

U.S. Serial No.: 09/294,298
Applicants: Richard L. Huganir, et al.
Filing Date: April 19, 1999
Group Art Unit: 1644
Examiner: Nolan, P.
Docket No.: 48235 (71699)

of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

Applicants believe that no fee is required for reinstatement of this application. However, if a fee is required, the Commission is hereby authorized to charge Deposit Account No. 04-1105.

Respectfully submitted,



Robert L. Buchanan (Reg. No. 40,927)
Attorney for Applicants
Dike, Bronstein, Roberts & Cushman,
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P. O. Box 9169
Boston, MA 02209
Tel.: (617) 439-4444
Fax: (617) 439-4170 / 7748

BOS2_344316